HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Pfister, M. Articles by Barrett, J. S. Search for Related Content PubMed PubMed Citation Articles by Pfister, M. Articles by Barrett, J. S. Social Bookmarking                   What's this?

Optimizing Dose Selection with Modeling and Simulation: Application to the Vasopeptidase Inhibitor M100240

From Drug Innovation and Approval, Aventis Pharmaceuticals, Bridgewater, New Jersey (Dr. Pfister, Dr. Haskell); University of New Jersey Medical and Dental School, New Brunswick (Dr. Martin); and the Children's Hospital of Philadelphia, Pennsylvania (Dr. Barrett).

Dual inhibition of neutral endopeptidase 24.11 (NEP) and angiotensin-converting enzyme (ACE) has gained increasing interest in the treatment of hypertension, heart failure, and renoprotection. Specifically, M100240, the thioester of the dual ACE/NEP inhibitor MDL100,173, has been evaluated in the management of hypertension. A model-based analysis, including simulations, was employed to characterize the relationship between individual M100240 drug exposure and neurohormonal response and to optimize the dose selection for future clinical studies. Sixty-two healthy subjects and 189 hypertensive patients were studied after oral once-daily administration of 2.5, 5, 10, 25, or 50 mg M100240. Pharmacokinetic-biomarker and blood pressure response models were fitted to the data with the computer program NONMEM. A direct inhibitory E_max model adequately described the relationship between MDL100,173 concentration and ACE activity. No clear concentration or dose-dependent NEP or blood pressure responses were evident. Given a target 90% ACE inhibition, simulation reveals that (1) 50 mg M100240 once daily produces adequate ACE inhibition 24 hours postdose in only 20% of subjects, and (2) higher and/or more frequent doses on the order of 25 mg three times daily or 50 mg twice daily are required to achieve the target ACE inhibition in at least 50% of patients over 24 hours. Insufficient blood pressure-lowering effects were observed in healthy subjects and hypertensive patients due to inadequate ACE and NEP inhibition with once-daily oral doses of up to 50 mg of M100240. Divided doses might provide target ACE inhibition in more patients.

Key Words: Vasopeptidase inhibitor • NEP inhibition • ACE inhibition • angiotensin • hypertension • NONMEM • modeling • simulation

Address for reprints: Marc Pfister, MD, FCP, Aventis Pharmaceuticals, 1041 Route 202-206, Bridgewater, NJ 08807.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				G. Dai, M. Pfister, A. Blackwood-Chirchir, and A. Roy Importance of Characterizing Determinants of Variability in Exposure: Application to Dasatinib in Subjects With Chronic Myeloid Leukemia J. Clin. Pharmacol., November 1, 2008; 48(11): 1254 - 1269. [Abstract] [Full Text] [PDF]

				A. Roy, D. R. Mould, X.-F. Wang, L. Tay, R. Raymond, and M. Pfister Modeling and Simulation of Abatacept Exposure and Interleukin-6 Response in Support of Recommended Doses for Rheumatoid Arthritis J. Clin. Pharmacol., November 1, 2007; 47(11): 1408 - 1420. [Abstract] [Full Text] [PDF]